Effects of meturedepa (NSC-51325) in 233 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
D000477:Alkylating Agents / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use* / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy
D000477:Alkylating Agents; D001389:Azirines; D002219:Carbamates